UPLOAD Filing
TENAX THERAPEUTICS, INC.
Date: April 18, 2025 · CIK: 0000034956 · Accession: 0000000000-25-004165
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286557
Letter
Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286557 Dear Christopher Giordano:
April 18, 2025
Christopher Giordano Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Lorna A. Knick
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 18, 2025 Christopher Giordano Chief Executive Officer Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300 Chapel Hill, NC 27517 Re: Tenax Therapeutics, Inc. Registration Statement on Form S-3 Filed April 15, 2025 File No. 333-286557 Dear Christopher Giordano: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lorna A. Knick </TEXT> </DOCUMENT>